文献速递血脂与心血管预防冠心病

固定剂量复方制剂对心血管死亡和事件的全球影响:2023-2050年建模研究

Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050: A Modeling Study.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

该建模研究评估了2023至2050年间广泛采用他汀联合降压药的单片复方制剂(SPC)对182个国家缺血性心脏病和卒中相关死亡及非致命事件的影响。SPC可降低全因过早死亡率2.0%至3.2%,有助于实现全球健康目标。

要点

  • SPC可降低全因过早死亡率2.0%(靶向)至3.2%(人群)。

核心结论

  • 广泛采用SPC疗法可显著加速降低心血管疾病死亡率,尤其在预防药物使用率低的地区。

研究设计与样本

  • 使用状态转移和人口学建模方法,预测182个国家2023至2050年缺血性心脏病和卒中相关死亡及非致命事件。
  • 比较两种SPC推广场景与非SPC(当前)护理:靶向策略(提高已就医者依从性、减少治疗惰性)和人群策略(向中高风险人群提供SPC)。
  • 围绕采纳率、长期依从性和阿司匹林效果假设进行敏感性分析。

主要发现

  • 南亚、东亚及太平洋地区因人口规模,可预防的致命和非致命事件份额最大。
  • SPC可降低全因过早死亡率2.0%(靶向)至3.2%(人群),促进全球健康目标实现。

临床怎么用

  • 在预防药物使用率低的地区,推广SPC疗法可能大幅减少心血管死亡和事件。
  • 可考虑靶向策略改善已就医患者的依从性,或人群策略覆盖中高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uptake of drugs for primary and secondary prevention of cardiovascular disease is low in many countries. Single-pill combination (SPC) therapies consisting of a statin and 1 or more antihypertensive drugs, with or without aspirin, can reduce rates of fatal and nonfatal cardiovascular disease, but their use is currently limited. OBJECTIVES: The authors modeled the potential impact of widespread adoption of SPC therapies over 2023 to 2050. METHODS: We used state-transition and demographic modeling approaches to project ischemic heart disease- and stroke-related deaths and nonfatal events in 182 countries. We modeled the effects of programs to roll out primary and secondary prevention SPCs in 2 scenarios, compared to non-SPC (current) care: 1) targeted strategies to improve adherence and reduce therapeutic inertia among persons already in care; and 2) population-based strategies to provide SPC therapies to most persons at intermediate-to-high risk. We conducted sensitivity analyses around our assumptions on adoption, long-term adherence, and the effect of aspirin. RESULTS: Over 2023-2050, use of SPC therapies could prevent up to 29 million deaths and 51 million cases in the targeted scenario and up to 72 million deaths and 130 million cases in the population scenario. The greatest share of fatal and nonfatal events prevented would be in South and East Asia and the Pacific because of population size. SPC therapies could reduce all-cause premature mortality by 2.0% (targeted) to 3.2% (population), facilitating achievement of global health targets. CONCLUSIONS: SPC therapies could substantially accelerate progress on cardiovascular disease mortality by increasing use of preventive drugs, especially in settings where uptake is currently low.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Watkins DA, Pickersgill SJ, Flood D, et al. Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050: A Modeling Study. J Am Coll Cardiol. 2025. PMID: 40669952. doi:10.1016/j.jacc.2025.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。